R-Pharm will market the Midatech drugs to potential new customers and give additional promotion in existing accounts.
Mark Pavoa, R-Pharm US’s chief executive, said: “Zuplenz and Oravig are complementary to our oncology franchise, which includes Ixempra.
“Cancer patients and treatment teams face many challenges as they battle the disease, and we are proud to represent these two additional potential solutions.”
Zuplenz is an oral soluble film formulation of the 5-HT3 receptor antagonist ondansetron that can prevent the nausea and vomiting associated chemotherapy and radiotherapy.
Oravig is the only once-daily local therapy available for treatment of oral thrush in adults.
Midatech acquired Nasdaq-listed Dara at the end of 2015 to give it a US distribution network to market its range of products to help patients undergoing cancer treatment.
Story by ProactiveInvestors